Juvenile idiopathic arthritis


Juvenile idiopathic arthritis is an umbrella term for chronic autoimmune arthropathies of unknown aetiology with onset of symptoms before the age of 16 years. Comprising several clinically distinct subtypes, juvenile idiopathic arthritis is the most common form of childhood arthritis.

Latest Research and Reviews

  • Research | | open

    DEK is a secreted protein abundant in the synovia of patients with juvenile idiopathic arthritis. Here the authors show DEK is important for neutrophil extracellular trap formation and joint inflammation, and demonstrate therapeutic efficacy of DEK-targeting aptamers in a mouse model of arthritis.

    • Nirit Mor-Vaknin
    • , Anjan Saha
    • , Maureen Legendre
    • , Carmelo Carmona-Rivera
    • , M Asif Amin
    • , Bradley J. Rabquer
    • , Marta J. Gonzales-Hernandez
    • , Julie Jorns
    • , Smriti Mohan
    • , Srilakshmi Yalavarthi
    • , Dave A. Pai
    • , Kristine Angevine
    • , Shelley J. Almburg
    • , Jason S. Knight
    • , Barbara S. Adams
    • , Alisa E. Koch
    • , David A. Fox
    • , David R. Engelke
    • , Mariana J. Kaplan
    •  & David M. Markovitz
  • Reviews |

    Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic disease, most notably systemic juvenile idiopathic arthritis. Findings from studies in animal models and from clinical observations, particularly in relation to the effects of anticytokine biologic therapies, have led to new concepts of the pathophysiology of this phenomenon.

    • Alexei A. Grom
    • , AnnaCarin Horne
    •  & Fabrizio De Benedetti
  • Reviews |

    The most common form of eye inflammation associated with juvenile idiopathic arthritis (JIA) is chronic anterior uveitis, which, if inadequately treated, can lead to ocular complications, including blindness. Sen and colleagues discuss the epidemiology, immunopathogenesis and management of JIA-associated uveitis, and describe the potential for biomarkers to improve its treatment.

    • Ethan S. Sen
    • , Andrew D. Dick
    •  & Athimalaipet V. Ramanan
  • Reviews |

    Treatment of children with juvenile idiopathic arthritis (JIA) is often marred by therapeutic inefficacy and considerable adverse effects. In this Review, the authors highlight the importance of identifying new pharmacogenomics biomarkers by applying modern genome analysis to large cohorts of JIA patients, with the objective of improving safety of existing therapies and providing new drug targets for the treatment of JIA.

    • Heinrike Schmeling
    • , Gerd Horneff
    • , Susanne M. Benseler
    •  & Marvin J. Fritzler
  • Reviews |

    The treatment of juvenile idiopathic arthritis (JIA) has improved markedly in past years, but sustained remission off-medication is still rare. In this Review, Hinze et al. discuss existing treatment approaches and guidelines, with a focus on targeted and patient-centred therapies developed to optimize management strategies for patients with JIA.

    • Claas Hinze
    • , Faekah Gohar
    •  & Dirk Foell

News and Comment